HSA Clinical Evaluation Requirements under GN-20 R2

1. Key takeaways

Clinical evaluation in Singapore follows GN-20 R2, Guidance on Clinical Evaluation, issued in November 2022. Class C and Class D devices are normally required to submit clinical evaluation evidence, while for Class B the requirement depends on the intended use and the risk profile. Where the Abridged or Expedited route is used, the clinical section may be filed as a summary that relies on the assessment conclusions of the reference agency; where the Full route is used, complete evidence must be submitted. The clinical module is one of the blocks of the ASEAN CSDT dossier and has to corroborate the risk management file and the Essential Principles checklist.

• GN-20 R2 of November 2022 is the governing guidance. It is applied within the GN-17 R5 or GN-18 R5 submission format of October 2026.
• Class C and Class D normally require clinical evaluation evidence at submission. Class B is assessed case by case against intended use and risk.
• On the Abridged and Expedited routes the clinical and pre-clinical chapters may be summarised with reference to the reference agency’s conclusions.
• On the Full route the complete evidence set is required, and a summary will not substitute for it.
• The clinical evaluation is an argument that connects intended use, claims and evidence, not merely a clinical trial report.

2. Legal basis

GN-20 R2 defines what a clinical evaluation is expected to contain and how it is documented for Singapore registration. It is applied inside the submission format set by GN-17 R5 for general devices and GN-18 R5 for IVD devices, both of October 2026, and it sits alongside the Essential Principles checklist under GN-16 R4 and the risk management file prepared under ISO 14971. The three documents are reviewed as a set, because the clinical evaluation justifies claims that the Essential Principles checklist asserts and that the risk management file relies on when it evaluates residual risk.

The distinction between routes is documentary rather than substantive. The obligation to hold clinical evidence does not disappear on a simplified route; what changes is the depth of what is filed, with the summary standing in for the full report on the strength of the reference agency’s prior assessment. That arrangement only works while the product remains the same as the one the reference agency assessed, which is why the route qualification and the labelling comparison sit close together in practice. Regulatory information in this article was verified to 26 October 2026 against secondary sources, namely GN-20 R2 and the GN-17 R5 / GN-18 R5 submission guidance.

3. Expert insights

Clinical evaluation is an argument, not a clinical trial report. This is the most fundamental misunderstanding we encounter. Under GN-20 R2 the clinical evaluation is a chain of reasoning: it starts from the intended use, identifies the claims that need clinical support, and then assesses whether the available evidence is sufficient to support them. That evidence may be literature, data on an equivalent device, post-market data or a clinical investigation. Whether a trial was run is a different question from whether an evaluation was performed, and a well-constructed evaluation can legitimately rest on literature and equivalence.

The Class B position is conditional, and the condition has to be argued. For a Class B product it is not safe to assume that no clinical evidence is needed. The correct approach is to state explicitly in the submission why clinical data are or are not required, and to set out that reasoning in the document itself rather than leaving the point implicit. An empty section is worse than a weak argument, because the reviewer cannot distinguish an omission from a considered judgement that clinical data are unnecessary. A short written justification removes that ambiguity entirely.

On the simplified and accelerated routes the summary must point to verifiable conclusions. When the clinical chapter is filed as a summary, it has to cite clearly the assessment conclusions of the reference agency on which it relies. A summary is not an omission: HSA retains the ability to request the full material that is being referenced. We therefore assemble an evidence pack in parallel with the summary, indexed to the same headings, so that a query can be answered by retrieval rather than by reconstruction. Building the pack after the question arrives is where timelines are lost.

Clinical evidence for IVDs follows a different logic from general devices. For an IVD the clinical evidence is organised around analytical performance and clinical performance. Analytical performance covers precision, accuracy, limit of detection, interference and stability; clinical performance covers sensitivity, specificity and predictive values. That structure is not interchangeable with the effectiveness endpoints used for therapeutic devices, and a dossier written on the therapeutic pattern will leave the analytical performance section thin precisely where an IVD reviewer looks first.

Clinical evaluation and post-market data form a closed loop. The evaluation is not a one-time exercise. Adverse events reported after market entry, complaint trends and PSUR data, which for Class C and Class D devices are normally prepared every two years, feed back into the conclusions of the clinical evaluation. When we build a quality system for a client we register the clinical evaluation report as a controlled document with a defined update cycle, rather than treating it as an archived deliverable that is completed once and filed.

4. Practical recommendations

• Build the clinical evaluation as an argument document, working backwards from intended use and claims to the evidence that each claim requires.
• Write the justification for Class B even when the conclusion is that clinical data are not required, and place it in the submission rather than in an internal note.
• Prepare an evidence pack alongside any summary submission, indexed to the same headings, so that an HSA query can be met by retrieval.
• Structure IVD submissions on the two axes of analytical performance and clinical performance, and populate both before drafting the conclusion.
• Register the clinical evaluation report as a controlled document with a periodic update cycle, linked to vigilance data.

5. Verification checklist

• □ Clinical evaluation argument chain established in accordance with GN-20 R2.
• □ Clinical evidence complete for Class C and Class D devices.
• □ Class B position on clinical data argued in writing within the submission.
• □ Summary plus evidence pack prepared where the Abridged or Expedited route is used.
• □ IVD evidence covers both analytical performance and clinical performance.
• □ Clinical evaluation report included in the periodic update mechanism.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com